The economics of medication safety: Improving medication safety through collective, real-time learning

Katherine de Bienassis, Laura Esmail, Ruth Lopert and Niek Klazinga
Additional contact information
Katherine de Bienassis: OECD
Laura Esmail: OECD
Ruth Lopert: OECD
Niek Klazinga: OECD

No 147, OECD Health Working Papers from OECD Publishing

Abstract: Poor medication practices and inadequate system infrastructure—resulting in poor adherence, medication-related harms, and medication errors—too often results in patient harm. As many as 1 in 10 hospitalizations in OECD countries may be caused by a medication-related event and as many one in five inpatients experience medication-related harms during hospitalization. Together, costs from avoidable admissions due to medication-related events and added length of stay due to preventable hospital-acquired medication-related harms total over USD 54 billion in OECD countries. This report includes four components; it 1) assess the human impact and economic costs of medication safety events in OECD countries, 2) explores opportunities to improve prescribing practices 3) examines the state-of-the art in systems and policies for improving medication safety, and 4) provides recommendations for improving medication safety at the national level.

JEL-codes: H51 I11 I18 L86 (search for similar items in EconPapers)
Date: 2022-09-14
New Economics Papers: this item is included in nep-hea
References: Add references at CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1787/9a933261-en (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:oec:elsaad:147-en

Access Statistics for this paper

More papers in OECD Health Working Papers from OECD Publishing Contact information at EDIRC.
Bibliographic data for series maintained by ().